HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced 2025 fiscal year results, recording $548.5 million in consolidated total revenue, down 13% year‑over‑year. Despite the decline, key products delivered 5% growth to $524.7 million, with FRUZAQLA (surufatinib) expanding 26% globally on Takeda’s commercialization strength, marking the company’s third consecutive profitable year.
Revenue Performance Summary
Segment
2025 Revenue
Change (YOY)
Key Drivers
Total Revenue
$548.5 M
–13%
Absence of 2024 Takeda milestone; China pricing pressure
Product Sales
$524.7 M
+5%
FRUZAQLA global expansion; H2 China recovery
Oncology Product Revenue
$214.4 M
–21%
$20 M 2024 milestone non‑recurring; NRDL pricing
Other Oncology/Immunology
$71.1 M
—
Milestones, licensing, R&D services
Other Business
$263.0 M
Flat
Prescription drug distribution steady
Product‑Level Performance
Product
Market
2025 Sales
Change
Strategic Notes
FRUZAQLA (surufatinib)
Global (Takeda)
$366.2 M
+26%
38 countries approved; 15+ launches in 2025 including Portugal, Belgium, South Korea, Mexico
Elunate (surufatinib)
China
$100.1 M
–13%
H2 rebound +33% vs. H1; NRDL pricing impact annualized
Orpathys (savolitinib)
China
—
—
3rd lung cancer indication approved; $11 M milestone from AstraZeneca
Sulanda
China
—
—
Neuroendocrine tumor franchise stable
Regional Dynamics
Region
Trend
Commentary
International (Takeda‑led)
Strong growth
FRUZAQLA launches in Europe, Asia, Americas accelerating; regulatory momentum in 38 markets
Pipeline Optionality: Sovleplenib approval would diversify revenue beyond oncology into hematology
Forward‑Looking Statements This brief contains forward‑looking statements regarding product performance, regulatory timelines, and revenue projections for HutchMed. Actual results may differ due to pricing pressures, competitive dynamics, and approval delays.-Fineline Info & Tech
By Fineline Cube 